http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#Head http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#provenance http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#pubinfo http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion http://purl.obolibrary.org/obo/DOID_9477 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9477 http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09075 http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association http://www.w3.org/2000/01/rdf-schema#label savaysa is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 1 1 limitation of use for nvaf savaysa should not be used in patients with creatinine clearance crcl 95 ml min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 6 mg 1 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant 1 2 savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvaf savaysa should not be used in patients with crcl 95 ml min because of an increased risk of ischemic stroke compared to warfarin see dosage and administr ation 2 1 warnings and precautions 5 1 clinical studies 14 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09075 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#provenance http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#pubinfo http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig http://purl.org/nanopub/x/hasSignature C88vhWrH8UxGbJwQ4mgedWcZXLu7YzDDfg24doYBbNFjR6j2bRyT+3Bk7LSuwdh/A67R9r7OFHLO9+M7sDOoAa5y2U2RIUNfKMmnpLFR1nQurqhtwtgqgvYMBs+n+A6XBI+SBc3vR4dKVCCmn3S7Xme3jEJzE3f1Mv3T9oykF/Y= http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://purl.org/dc/terms/created 2021-07-03T14:45:03.647+02:00 http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs